FDA Reverses Decision, Will Review Moderna's mRNA Flu Vaccine Application

In Brief

The FDA has agreed to review Moderna's mRNA flu vaccine after initially declining the application.

Key Facts

• The FDA initially declined to review Moderna's application for a new mRNA-based flu vaccine.
• Moderna publicly stated the FDA refused to consider its application for the vaccine.
• The refusal did not cite any safety or efficacy concerns, according to Moderna's CEO.
• Following further discussions, the FDA reversed its decision and will now review the application.
• Moderna aims to make the vaccine available for the 2026-27 flu season.

What Happened

Moderna submitted an application for a new flu vaccine using mRNA technology, which the FDA initially declined to review. After additional discussions between Moderna and regulators, the FDA reversed its decision and will now review the application.

Why It Matters

The FDA's initial refusal and subsequent reversal could impact the approval process for new vaccines in the US. The outcome may influence future regulatory approaches to mRNA-based vaccines and affect public health strategies for flu prevention.